TFF Pharmaceuticals (TFFP) Stock Price, News & Analysis

Company Overview

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.

Key Stats

• Today's Range: $0.07 to $0.07
• 50-Day Range: $0.07 to $0.07
• 52-Week Range: $0.06 to $3.23
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $288.60 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TFFP Stock Analysis - Frequently Asked Questions

How were TFF Pharmaceuticals' earnings last quarter?

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) announced its earnings results on Wednesday, November, 20th. The company reported ($0.81) earnings per share (EPS) for the quarter.

When did TFF Pharmaceuticals' stock split?

TFF Pharmaceuticals's stock reverse split on Tuesday, December 19th 2023.The 1-25 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did TFF Pharmaceuticals IPO?

TFF Pharmaceuticals (TFFP) raised $22 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 4,400,000 shares at $5.00 per share. National Securities served as the underwriter for the IPO.

What other stocks do shareholders of TFF Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TFF Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), CymaBay Therapeutics (CBAY), GE Aerospace (GE), CrowdStrike (CRWD) and Adobe (ADBE).

Company Calendar

• Last Earnings: 11/20/2024
• Today: 8/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TFFP
• CIK: 1733413
• Web: www.tffpharma.com
• Phone: 817-438-6168
• Fax: N/A
• Employees: 19
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $730 thousand
• Price / Sales: 0.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.04 per share
• Price / Book: 0.02

Miscellaneous

• Outstanding Shares: 4,440,000
• Free Float: 4,244,000
• Market Cap: $288.60 thousand
• Optionable: Optionable
• Beta: N/A